according to the results of a retrospective analysis conducted by researchers at Memorial Sloan Kettering. Their analysis included 396 patients, 14.1% of which received treatment with Opdivo, while the rest received Keytruda (pembrolizumab).
Taking Opdivo and Yervoy together results in stronger T-cell function that exceeds the effects of either medication alone. This is because they work in different ways. Patients who have taken these two medications together saw improved anti-tumor responses in metastatic melanoma and advanced RCC. In...